









Markets
/
Stocks
/
nasdaq-scyx
/

SCYNEXIS Inc

SCYX

1.120USD

+0.030+2.75%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

43.88MMarket Cap

LossP/E TTM



SCYNEXIS Inc

1.120

+0.030+2.75%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

75 / 175

Overall Ranking

224 / 4720

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 3 analysts

Buy

Current Rating

4.667

Target Price

+328.13%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

SCYNEXIS, Inc. is a biotechnology company. It is pioneering medicine to overcome and prevent difficult-to-treat and drug-resistant infections. It develops antifungal platform fungerps, a novel class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have generally shown in vitro and in vivo activity against a range of human fungal pathogens, such as Candida and Aspergillus genera, including multidrug-resistant strains, and Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and common mucorales species. Ibrexafungerp is the first representative of this novel class of antifungals with additional assets from the fungerp family, including SCY-247, in preclinical stages of development. The United States Food and Drug Administration approved BREXAFEMME for treatment of patients with vulvovaginal candidiasis, also known as vaginal yeast infection, and for the reduction in the incidence of recurrent vulvovaginal candidiasis.

Growing

The company is in a growing phase, with the latest annual income totaling USD 3.75M.

Turnaround to Loss

The company's performance has turned to a loss, with the latest annual loss of USD 21.29M.%!(EXTRA int=2)

Undervalued

The company’s latest PE is -2.83, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 12.22M shares, decreasing 20.52% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 1.66M shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 6.48, which is lower than the Pharmaceuticals industry's average of 7.84. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 1.36M, representing a year-over-year increase of 85.33%, while its net profit experienced a year-over-year increase of 52.38%.

Score

Industry at a Glance

Previous score

6.48

Change



Financials

6.67

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.85

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.84

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.86

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.20

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 1.20, which is lower than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is -2.75, which is -131.94% below the recent high of 0.88 and 36.74% above the recent low of -1.74.

Score

Industry at a Glance

Previous score

1.20

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 75/175

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.67, which is higher than the Pharmaceuticals industry's average of 7.78. The average price target for SCYNEXIS Inc is 4.00, with a high of 6.00 and a low of 4.00.

Score

Industry at a Glance

Previous score

8.67

Change

Support & Resistance

No Data

Analyst Rating

Based on 3 analysts

Buy

Current Rating

4.667

Target Price

+328.13%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

179

Total

Median

Average

Company name

Ratings

Analysts

SCYNEXIS Inc

SCYX

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Alnylam Pharmaceuticals Inc

ALNY

Eli Lilly and Co

LLY

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 7.39, which is higher than the Pharmaceuticals industry's average of 6.84. Sideways: Currently, the stock price is trading between the resistance level at 1.33 and the support level at 0.82, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.39

Change

1.38

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(0)

Neutral(3)

Buy(4)

Indicators

Value

Direction

MACD(12,26,9)

0.024

Buy

RSI(14)

65.996

Neutral

STOCH(KDJ)(9,3,3)

49.105

Neutral

ATR(14)

0.087

High Vlolatility

CCI(14)

75.613

Neutral

Williams %R

38.000

Buy

TRIX(12,20)

1.382

Buy

StochRSI(14)

63.495

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

1.072

Buy

MA10

1.058

Buy

MA20

0.950

Buy

MA50

0.840

Buy

MA100

0.838

Buy

MA200

0.950

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Pharmaceuticals industry's average of 6.26. The latest institutional shareholding proportion is 31.31%, representing a quarter-over-quarter decrease of 1.60%. The largest institutional shareholder is The Vanguard, holding a total of 1.66M shares, representing 3.95% of shares outstanding, with 9.75% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Federated Hermes Global Investment Management Corp.

2.90M

Kingdon Capital Management, L.L.C.

2.24M

The Vanguard Group, Inc.

Star Investors

1.66M

-0.29%

Avidity Partners Management LP

1.23M

Acadian Asset Management LLC

443.06K

-5.18%

Geode Capital Management, L.L.C.

419.49K

+3.56%

Bridgeway Capital Management, LLC

353.49K

-16.53%

BlackRock Institutional Trust Company, N.A.

416.84K

-0.41%

Angulo (Gonzalez David)

323.28K

+7.66%

AMH Equity, Ltd.

627.04K

+0.16%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.18, which is lower than the Pharmaceuticals industry's average of 4.07. The company's beta value is 1.71. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.